Half-dose aprotinin does not affect haemorheological properties in patients undergoing bypass surgery

Coron Artery Dis. 1996 Aug;7(8):609-13. doi: 10.1097/00019501-199608000-00008.

Abstract

Objective: To investigate haemorheological changes in patients undergoing coronary artery bypass grafting and to determine whether the protective effect on haemorheology of high-dose aprotinin also exists under a half-dose regimen.

Methods: Forty patients were studied in a double-blind, placebo-controlled study design. Patients in the aprotinin group received half of the standard high dose of aprotinin during surgery. Erythrocyte and white-cell clogging rates as well as whole blood and plasma viscosity were measured. Viscosity results were expressed as a ratio to the viscosity of saline.

Results: Erythrocyte and white-cell clogging rates were increased significantly, whereas whole blood and plasma viscosity were decreased significantly during cardiopulmonary bypass. The reduction in viscosity had a strong correlation to haemodilution. There was no significant difference in any of the measured variables between the aprotinin and the placebo groups.

Conclusion: This study showed that blood cell damage occurred during cardiopulmonary bypass surgery, as measured by a raised clogging rate. This tendency was the same in both groups and therefore no increased potential for microthrombi could be attributed to aprotinin haemorheologically. However, half-dose aprotinin did not show any preserving effect in haemorheology when the blood-cell clogging rate and blood viscosity were studied.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aprotinin / administration & dosage
  • Aprotinin / therapeutic use*
  • Blood Coagulation / drug effects*
  • Blood Viscosity / drug effects*
  • Coronary Artery Bypass*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Hemostatics / administration & dosage
  • Hemostatics / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Reference Values
  • Treatment Outcome

Substances

  • Hemostatics
  • Aprotinin